Drugs / ICP-033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05367232 | Feb 2022 → Dec 2024 | — | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05367232 ↗ |
| Route | Oral | “Administered orally, once a day, 28 days per cycle” NCT05367232 ↗ |